Register of
Medicinal Products

Product class: Authorized package
Medicinal product class: For human use
Package code: 1826210
Name of medicinal product: LIVOGIVA
Active substances:
Teriparatide
Estonian, English, Latin
ATC code: H05AA02
Dosage form: solution for injection in pre-filled pen
Route of administration: subcutaneous use
Strengh: 20mcg 80mcl
Amount in package: 2.7ml 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Livogiva is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures have been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
Safety features: Yes
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Labelling:  
Last imported to Estonia: Never imported to Estonia
: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Patients and healthcare professionals are asked to report any suspected adverse reactions to State Agency of Medicines.State Agency of Medicines
Marketing authorization holder: Theramex Ireland Limited 
Marketing authorization number: EU/1/20/1462 
Marketing authorization issued on: August 27, 2020 
Marketing authorization expires on: August 28, 2025 
Marketing authorization procedure type: Centralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: September 11, 2020
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere